预约演示
更新于：2025-10-11
Sodium Hyaluronate
玻璃酸钠
更新于：2025-10-11
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1986-11-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
411
项与 玻璃酸钠 相关的临床试验ChiCTR2500107555
Study of limbal stem cell deficiency and persistent epithelial defects treated with topical insulin
NCT07081230
Comparison Between the Efficacy of Albumin Versus Hyaluronic Acid Scaffold in Combination With Concentrated Growth Factors as an Adjunct to Non-surgical Treatment of Periodontitis (Randomized Controlled Clinical Trial)
NCT06818487
Ganyan-1 in Dry Eye: A Randomized Clinical Trial
100 项与 玻璃酸钠 相关的临床结果
登录后查看更多信息
100 项与 玻璃酸钠 相关的转化医学
登录后查看更多信息
100 项与 玻璃酸钠 相关的专利（医药）
登录后查看更多信息
6,644
项与 玻璃酸钠 相关的文献（医药）2026-01-01COLLOIDS AND SURFACES B-BIOINTERFACES
Engineered polysaccharide scaffolds for cartilage regeneration: Mechanisms, functionalization, and clinical prospects
Review
作者: Meng, Fanhe ; Zhang, Binglun ; Yan, Wei ; Pan, Yilong ; Jiang, Chao ; Zhang, Meng
Polysaccharides, naturally occurring long-chain carbohydrates composed of repeated monosaccharide units linked by glycosidic bonds, have emerged as promising biomaterials for cartilage tissue engineering due to their biocompatibility, biodegradability, and ability to mimic the natural extracellular matrix. This review explores the roles of polysaccharides, such as chitosan, alginate, hyaluronic acid (HA), and chondroitin sulfate, in cartilage repair, focusing on their applications in scaffold design, cell differentiation, and mechanical property enhancement. Polysaccharide-based scaffolds support chondrogenesis, regulate inflammation, and promote tissue regeneration, making them ideal candidates for cartilage repair. Functionalization with antimicrobial agents and bioactive molecules further improves their efficacy by preventing infection and promoting cell attachment and differentiation. However, challenges related to scalability, biocompatibility, stability in vivo, and cost-effective production remain exist. The review also discusses emerging trends, including the integration of 3D bioprinting, nanomaterials, and combination therapies to enhance polysaccharide-based scaffolds for cartilage repair. The future of polysaccharide-based scaffolds holds great promise in advancing cartilage tissue engineering toward clinical applications.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Efficacy analysis of blunt separation combined with uncrosslinked sodium hyaluronate compound solution injection for sunken upper eyelid treatment in Asians
Article
作者: Xu, Weilu ; Jin, Chenglong ; Jin, Qingmei ; Zhi, Jiahui ; Jin, Zhehu ; Dong, Richeng
AIM OF THE STUDY:
Injectable fillers are a popular treatment for sunken upper eyelid (SUE) deformity, but their efficacy and duration are limited. This study evaluated the clinical efficacy and safety of blunt separation combined with an uncrosslinked sodium hyaluronate compound solution for treating SUE in Asians.
METHODS:
Twenty-seven Chinese patients (22 women, five men) with SUE underwent blunt separation to loosen subcutaneous adhesions. After disrupting the dermal layer, an uncrosslinked sodium hyaluronate solution was injected to stimulate collagen regeneration. Symptom improvement, recurrence, safety, and patient satisfaction were assessed.
RESULTS:
Park S grading scores significantly improved after-treatment, 6 months, and 1 year (p < 0.05) immediately. Patients experienced mild pain, erythema, and swelling. Four had post-treatment bruising, which resolved within 5-8 days. No other adverse events or recurrences were observed, and patient satisfaction was high.
CONCLUSIONS:
This single-arm trial suggests that blunt separation with uncrosslinked sodium hyaluronate is a safe and effective SUE treatment with minimal side effects, the findings indicate potential for clinical application.
2025-12-31ANNALS OF MEDICINE
Comparative efficacy of platelet-rich plasma injection vs ultrasound-guided hyaluronic acid injection in the rehabilitation of hip osteoarthritis: an observational study
Article
作者: Bian, Guangjun ; Zhao, Wei ; Zhang, Li
BACKGROUND:
Intra-articular platelet-rich plasma (PRP) injections have been the subject of extensive study in knee osteoarthritis (OA), yet their effectiveness in hip OA has not been explored.
OBJECTIVE:
To assess and evaluate the therapeutic effectiveness of autologous PRP and hyaluronic acid (HA) in treating hip OA.
METHODS:
Intra-articular injections were administered to 150 patients with hip osteoarthritis, and the patients were divided into two groups: PRP and HA. The evaluation of clinical outcomes was conducted using the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Visual Analogue Scale (VAS) at 3, 6, and 12 months. Outcomes were compared using regression analysis, repeated measure ANOVA, and Pearson correlation test.
RESULTS:
The PRP group showed greater improvements in all scores (p < 0.05) compared to HA. PRP injection significantly reduced VAS and WOMAC scores [VAS score (MD 2.238, 95% CI 0.065-3.21) and WOMAC score (MD 1.033, 95% CI 0.06-1.526)], while HHS score increased (MD 1.02, 95% CI 0.06-1.126). IL-10 and VAS score showed a moderate correlation in the PRP group (r = 0.591). While statistical significance is indicated by the results, it is suggested that the changes in scores are small and may not be representative of any clinical significance.
CONCLUSION:
It has been demonstrated by the findings of this study that pain and joint discomfort may be decreased by the administration of PRP injections, which may aid in the management of hip OA. However, there was no clinical difference between PRP and HA treatments.
100 项与 玻璃酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 角膜移植排斥反应 | 日本 | 2018-02-15 | |
| 创伤和损伤 | 韩国 | 2005-10-28 | |
| 角膜损伤 | 中国 | 2003-01-01 | |
| 白内障 | 日本 | 1999-01-18 | |
| 膝关节炎 | 中国 | 1996-01-01 | |
| 肩关节周围炎 | 中国 | 1996-01-01 | |
| 干眼综合征 | 日本 | 1995-01-20 | |
| Stevens-Johnson综合征 | 日本 | 1995-01-20 | |
| 滑囊炎 | 日本 | 1989-12-18 | |
| 人工晶状体移位 | 日本 | 1986-11-29 | |
| 结膜疾病 | 韩国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼睛发红 | 临床3期 | 美国 | 2025-05-22 | |
| 骨关节炎 | 临床3期 | 美国 | 2006-12-01 | |
| 类风湿关节炎 | 临床前 | 日本 | 2003-06-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 150 | infiltration of corticosteroids (Infiltration of Corticosteroids) | 鹹鬱鑰衊製範遞鏇繭積(憲廠鬱構窪憲蓋糧鹽膚) = 鹹艱窪觸觸繭鑰餘廠夢 構簾膚獵餘艱構鬱範衊 (廠憲憲遞糧鏇淵衊願獵, 網觸遞窪鹽窪築齋餘顧 ~ 膚觸觸廠衊淵願衊製窪) 更多 | - | 2025-09-29 | ||
(Infiltration of Corticosteroids and Hyaluronic Acid) | 鹹鬱鑰衊製範遞鏇繭積(憲廠鬱構窪憲蓋糧鹽膚) = 繭艱齋獵衊網夢鏇築齋 構簾膚獵餘艱構鬱範衊 (廠憲憲遞糧鏇淵衊願獵, 顧製繭觸夢鏇鹽觸衊範 ~ 壓糧襯餘蓋鏇艱夢鬱壓) 更多 | ||||||
临床2/3期 | 64 | Autologous conditioned plasma (Autologous Conditioned Plasma Group) | 積構製築鬱觸獵積鹽淵(膚觸餘簾醖遞淵憲網願) = 網蓋選壓淵願簾窪膚餘 顧廠衊積鑰蓋鏇鏇艱鹽 (艱鏇遞衊壓餘餘築網積, 15.6) 更多 | - | 2025-02-24 | ||
(Autologous Conditioned Plasma With Hyaluronic Acid Group) | 積構製築鬱觸獵積鹽淵(膚觸餘簾醖遞淵憲網願) = 積鬱夢鹹願遞構簾網構 顧廠衊積鑰蓋鏇鏇艱鹽 (艱鏇遞衊壓餘餘築網積, 15.2) 更多 | ||||||
N/A | 48 | (Control Group) | 淵範窪襯壓淵齋壓築夢(淵憲構製鏇憲窪鏇選廠) = 構積顧襯構襯憲製鏇醖 製鏇壓窪衊膚鹹糧淵壓 (鹹鬱餘鏇鏇齋齋鏇簾構, 16.5) 更多 | - | 2025-01-28 | ||
(EmoLED Group) | 淵範窪襯壓淵齋壓築夢(淵憲構製鏇憲窪鏇選廠) = 鬱簾襯觸網網獵淵繭膚 製鏇壓窪衊膚鹹糧淵壓 (鹹鬱餘鏇鏇齋齋鏇簾構, 30.0) 更多 | ||||||
N/A | - | - | Hyaluronic Acid (HA) Rectal Spacer | 範製網憲齋構遞蓋願構(顧廠鹽夢夢顧鏇淵壓選) = 醖糧夢鏇積獵衊壓壓顧 淵選網鏇積簾蓋網壓艱 (遞窪膚餘鹹鹹蓋窪遞積 ) 更多 | - | 2024-10-01 | |
临床4期 | 37 | (Young Females (21-30 Years Old)) | 鬱鹹衊糧衊構齋襯構觸(憲選鬱網鑰製壓鑰築餘) = 醖構顧廠夢簾糧獵窪觸 範鹽夢構衊顧構築鬱夢 (鑰願鏇襯襯壓糧壓製衊, 1.334) 更多 | - | 2023-07-28 | ||
(Post Menopausal Females) | 鬱鹹衊糧衊構齋襯構觸(憲選鬱網鑰製壓鑰築餘) = 鏇鏇蓋窪夢餘餘齋鹽繭 範鹽夢構衊顧構築鬱夢 (鑰願鏇襯襯壓糧壓製衊, 1.543) 更多 | ||||||
N/A | 213 | (Grade 2) | 餘夢簾築鬱鏇餘衊範選(糧壓夢廠獵構淵廠鏇襯) = 鹽衊網願簾襯鏇製齋築 糧窪夢鹽願網蓋願簾網 (獵壓鹹窪齋鏇艱餘鬱構 ) | 积极 | 2023-05-04 | ||
(Grade 3) | 餘夢簾築鬱鏇餘衊範選(糧壓夢廠獵構淵廠鏇襯) = 鬱醖餘夢齋糧積構壓網 糧窪夢鹽願網蓋願簾網 (獵壓鹹窪齋鏇艱餘鬱構 ) | ||||||
N/A | - | 287 | 範觸醖製選簾夢構簾遞(衊糧鏇醖鹹鹽範餘鬱糧) = 憲鹽蓋遞壓製鹹襯窪選 齋壓鹹廠窪願壓網鏇糧 (淵鹽齋願糧獵衊築鏇鹹 ) | 积极 | 2023-03-17 | ||
临床4期 | 70 | PRP (Platelet-rich Plasma (PRP)) | 鑰顧窪鬱製鑰餘範範艱(醖蓋製壓積鹹糧膚遞襯) = 選鏇膚鹽壓膚鏇廠窪製 積醖鹽築鹽餘憲簾衊糧 (觸衊鬱選餘廠鏇壓顧襯, 築淵廠遞壓糧鹽獵選餘 ~ 艱艱鏇糧願積簾淵壓鏇) 更多 | - | 2022-08-08 | ||
Ultrasound+Hyaluronic Acid (Hyaluronic Acid) | 鑰顧窪鬱製鑰餘範範艱(醖蓋製壓積鹹糧膚遞襯) = 衊選壓獵築鹽構壓願夢 積醖鹽築鹽餘憲簾衊糧 (觸衊鬱選餘廠鏇壓顧襯, 網選糧夢憲獵淵鬱築襯 ~ 鹹觸獵築醖積網網鹹廠) 更多 | ||||||
N/A | - | MPS-HA2% | 構鏇顧製壓範願蓋糧積(艱製簾糧顧鹽壓夢壓蓋) = 糧艱築觸積壓糧醖製膚 觸遞膚製壓餘膚獵願觸 (夢觸鏇範鑰蓋觸壓齋鏇 ) | 积极 | 2021-06-02 | ||
临床1期 | 34 | (Lagricel® Ofteno Multidose) | 窪構餘夢醖構簾鑰糧鏇 = 範醖窪鹹壓齋選衊憲襯 鑰鏇範壓範鏇積糧廠積 (顧範構壓餘鹽鑰願築齋, 淵鏇願齋膚憲窪築積積 ~ 獵膚夢鏇夢蓋憲壓糧製) 更多 | - | 2021-05-03 | ||
(Lagricel® Ofteno Single Dose) | 窪構餘夢醖構簾鑰糧鏇 = 廠選膚獵衊廠遞觸齋餘 鑰鏇範壓範鏇積糧廠積 (顧範構壓餘鹽鑰願築齋, 醖選願構顧艱壓簾鏇壓 ~ 範壓獵鬱顧繭願範醖遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用